Biota Holdings Limited (ASX:BTA)
All other key markets for CS-8958 in the world, including the US, remain available for licensing by the partners. Biota and Daiichi Sankyo will share commercial returns from licensing outside Japan.
In 2003, Biota and Daiichi Sankyo merged their respective LANI programs and Daiichi Sankyo retained the option to manufacture and market CS-8958 in Japan in return for funding the Japanese trials. The molecule CS-8958 was discovered by Daiichi Sankyo.
Biota also announced that patient enrolment of the key Phase III studies in Asia had now been completed with results expected to be released mid year. The results from the earlier Phase II trial, reported on 31 July 2008, concluded that "inhaled CS-8958 administered once only was statistically indistinguishable from 75mg of oseltamivir administered twice daily for 5 consecutive days".
"I would like to congratulate our partners Daiichi Sankyo for their sustained commitment to the development of CS-8958. The compound will complement the world's anti-influenza drug arsenal and will address the recognised need for additional antivirals" said Peter Cook, Biota's Managing Director.
About LANI's (Long-Acting Neuraminidase Inhibitors)
Current neuraminidase inhibitors for influenza require daily or more frequent dosing.
The ability to dose patients on a weekly, or even less frequent, basis offers numerous benefits. Firstly, any stockpile of weekly-dosing drug will last longer and protect more people, in the case of an influenza pandemic. Additionally, a weekly dose may improve patient compliance over a more frequent regime.
About Daiichi Sankyo
Daiichi Sankyo Company, Limited was established in 2005 through the merger of two leading Japanese pharmaceutical companies.
*Further information, visit http://www.daiichisankyo.com
Daiichi-Sankyo Company Limited
Biota Holdings Limited